Blindness and severe vision impairments consecutive to eye disorders affect more than 200 million people worldwide. Indeed, current diagnoses are made too late, and treatments are not optimal for many diseases. The main reason is the difficulty of accurately detecting and monitoring the disease as well as assessing the treatment effect. This is due to the limitations of the standard imaging instruments unable to visualize the eye tissues with sufficient details.
At EarlySight, we have developed a unique ophthalmic camera that can observe the retina in detail, as if under a microscope. This advanced optical instrument creates images of the individual cells impacted by diseases. An AI software is in development to analyze these images and detect and monitor disease biomarkers. The perspective to precisely measure the degenerative process opens new avenues in the diagnosis, monitoring and treatment of disorders affecting the back of the eye.
Cellular resolution
Look at every detail in the eye
Digital data
AI-based objective structural measurement
Explore disease inception
Unique access to the deep eye layer (RPE)
The disruptive ophthalmic camera from EarlySight, delivers cellular level images of various structures of the retina and optic disc to explore and capture the eye anatomy in a completely new perspective.
Disruptive infrared transscleral flood illumination reveals hidden eye structures such as RPE.
With adaptive optics, look at single cells composing the tissue, as if under a microscope. Observe the retina anatomy in detail.
Easy switch between retinal pigment epithelium, photoreceptors, nerve fiber layer or retinal vessels image
Obtain widefield fundus overview image simultaneously with the cellular level image to easily locate the imaged area within the eye.
Manual and smooth operation with joystick allow for quick and efficient examinations.
Automatic storage of image location within the eye to easily perform follow-up examinations.
EarlySight’s Cellularis platform has already been endorsed by several renowned eye doctors.
We are deeply appreciative of the support and trust that our partners have shown us.
EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study Geneva, Switzerland and Paris, France, 9 October 2026 –
Geneva, Switzerland – [05/12/2025] – EarlySight SA (“EarlySight”), a Swiss medtech company pioneering cellular-level retinal imaging and biomarkers, is pleased to announce a strategic collaboration
We’re thrilled to announce the extension of our Seed round to 𝐂𝐇𝐅 6.1 𝐦𝐢𝐥𝐥𝐢𝐨𝐧, with Zürcher Kantonalbank joining our investor syndicate alongside Verve Ventures, Nina Capital,
